Health · 1 sources covering this

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/255339c0310552da31a6ae07bb7901e7affeab70"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Biotech&#8217;s next big bet: A Tenax study of a heart failure treatment"></iframe>

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

How 1 sources are covering this

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

More from Health

Covid can reactivate dormant viruses, according to study

STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it

Hospital staff said he was faking it and released him. He died from an overdose soon after

Most U.S. doctors avoid treating patients with addiction, leaving millions vulnerable

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Biotech&#8217;s next big bet: A Tenax study of a heart failure treatment

More from Health

Covid can reactivate dormant viruses, according to study

STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it

Hospital staff said he was faking it and released him. He died from an overdose soon after

Most U.S. doctors avoid treating patients with addiction, leaving millions vulnerable

Reader

Trust & legal

Across the network

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment